Organization Profile

You just read:

Published study results show that adding new immunotherapy elotuzumab to standard treatment for multiple myeloma significantly reduced risk of disease progression

News provided by

Bristol-Myers Squibb Canada

Jun 03, 2015, 05:59 ET